Skip to main content

Advertisement

Table 1 Demographic variables, clinical scores, and cerebrospinal fluid biomarker values at baseline examination, separated by diagnostic group

From: A language-based sum score for the course and therapeutic intervention in primary progressive aphasia

  HC nfvPPA svPPA lvPPA  
N Mean ± SD range N Mean ± SD range N Mean ± SD range N Mean ± SD range p value
Gender (female/male)   16/12   14/14   12/5   7/6 0.388
Handedness (left/right/mix)   1/26/1   3/25/0   1/15/1   1/11/1 0.688
Education (years) 27 13.89 ± 2.83 8–18 27 12.56 ± 3.41 4–20 16 14.69 ± 4.03 8–24 13 13 ± 3.51 8–20 0.140
Age at baseline (years) 28 67.72 ± 8.08 49.8–78.7 28 67.70 ± 7.72 51.5–78.2 17 63.26 ± 6.44 53.4–77.3 13 67.03 ± 5.25 57.8–73.8 0.073
Age of initial symptoms (years)    27 65.33 ± 8.35 47–78 14 58.36 ± 7.08 49–75 13 62.85 ± 5.93 54–72 0.022
Disease duration (years)    27 2.60 ± 1.78 0.2–8.9 14 4.01 ± 1.62 1.7–6.7 13 4.18 ± 4.68 0.4–17.7 0.040
MMSE 28 28.96 ± 0.79 27–30 26 22.73 ± 6.13 9–30 16 23.19 ± 5.47 12–30 13 20.23 ± 6.29 10–27 0.385
CDR 28 0.04 ± 0.13 0–0.5 22 2.77 ± 2.87 0–13 14 3.57 ± 2.76 0.5–10 10 3.0 ± 2.93 0–8.5 0.461
FTLD-CDR 28 0.05 ± 1.58 0–0.5 22 4.98 ± 3.64 0.5–18 14 5.79 ± 3.48 2.5–12.5 10 4.75 ± 3.59 1–11 0.561
Tau    19 456 ± 281 139–1045 13 322 ± 125 102–493 7 651 ± 403 208–1373 0.194
ptau    18 55 ± 30 24–141 13 47 ± 14 22–76 7 102 ± 71 16–239 0.091
Abeta1–42    19 585 ± 293 336–1376 13 866 ± 393 330–1601 7 525 ± 236 125–825 0.067
  1. p values correspond to Kruskal-Wallis tests, comparing the three primary progressive aphasia subgroups
  2. All cerebrospinal fluid levels are measured in pg/ml
  3. CDR Clinical Dementia Rating Scale, FTLD-CDR frontotemporal lobar degeneration-modified Clinical Dementia Rating Scale, HC healthy controls, lvPPA logopenic variant primary progressive aphasia, MMSE Mini-Mental State Examination, nfvPPA nonfluent variant primary progressive aphasia, ptau phospho tau, svPPA semantic variant primary progressive aphasia